Glaxo-Pfizer HIV Drug Helps Hard-to-Treat Patients
This article is for subscribers only.
An experimental treatment for HIV developed by GlaxoSmithKline Plc, Pfizer Inc. and Shionogi & Co. reduced the virus in hard-to-treat patients in a late-stage study, providing further support for a regulatory filing by the end of this year.
After 24 weeks on dolutegravir, 63 percent of 183 participants who had shown resistance to previous treatments had undetectable levels of the virus, the drugmakers’ HIV joint venture ViiV Healthcare Ltd. said in a statement today.